Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial
Sign Up to like & getrecommendations! Published in 2020 at "European Respiratory Journal"
DOI: 10.1183/13993003.congress-2020.5280
Abstract: Background: The long-term efficacy and safety of mepolizumab in severe eosinophilic asthma (SEA) have been shown. Aims: To assess the impact of stopping versus continuing long-term mepolizumab on asthma worsening. Methods: COMET (NCT02555371) was a… read more here.
Keywords: long term; asthma worsening; term mepolizumab; mepolizumab ... See more keywords